Susquehanna Fundamental Investments LLC Purchases New Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 83,193 shares of the specialty pharmaceutical company's stock, valued at approximately $10,245,000. Susquehanna Fundamental Investments LLC owned 0.14% of Jazz Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of JAZZ. Centre Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at $9,335,000. Moloney Securities Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the fourth quarter worth about $464,000. Franklin Resources Inc. boosted its holdings in Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after purchasing an additional 48,708 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its position in Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after purchasing an additional 4,332 shares during the period. Finally, BTC Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 9.4% during the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after buying an additional 4,271 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on JAZZ. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Needham & Company LLC reiterated a "buy" rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Barclays reissued an "overweight" rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Finally, Piper Sandler restated an "overweight" rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Stock Up 2.6 %

Jazz Pharmaceuticals stock traded up $3.05 during trading on Friday, reaching $120.23. 398,317 shares of the company's stock were exchanged, compared to its average volume of 802,253. The company's 50-day moving average is $123.02 and its two-hundred day moving average is $122.40. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The firm has a market cap of $7.41 billion, a price-to-earnings ratio of 16.93, a PEG ratio of 1.04 and a beta of 0.42.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now directly owns 440,307 shares of the company's stock, valued at approximately $54,487,991.25. This trade represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock worth $4,023,305. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.